Cargando…

Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives

SIMPLE SUMMARY: Glioblastoma is the most common and aggressive malignant primary brain cancer in adults. The prognosis remains poor following standard-of-care treatment with surgery, radiotherapy and chemotherapy, with a median overall survival of about 15 months. Theoretically, all glioblastoma pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Birzu, Cristina, French, Pim, Caccese, Mario, Cerretti, Giulia, Idbaih, Ahmed, Zagonel, Vittorina, Lombardi, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794906/ https://www.ncbi.nlm.nih.gov/pubmed/33375286 http://dx.doi.org/10.3390/cancers13010047

Ejemplares similares

A New Landscape for Systemic Pharmacotherapy of Recurrent Glioblastoma?
por: Lombardi, Giuseppe, et al.
Publicado: (2020)

Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study
por: Lombardi, Giuseppe, et al.
Publicado: (2021)

Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)
por: Padovan, Marta, et al.
Publicado: (2021)

Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study
por: Parrozzani, Raffaele, et al.
Publicado: (2020)

The role of radiation therapy and systemic treatments in meningioma: The present and the future
por: Caccese, Mario, et al.
Publicado: (2023)

Validation of the Comprehensive Geriatric Assessment as a Predictor of Mortality in Elderly Glioblastoma Patients
por: Lombardi, Giuseppe, et al.
Publicado: (2019)

Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study
por: Parrozzani, Raffaele, et al.
Publicado: (2020)

Clinical Management of Diffuse Low-Grade Gliomas
por: Lombardi, Giuseppe, et al.
Publicado: (2020)

PET/MR in recurrent glioblastoma patients treated with regorafenib: [(18)F]FET and DWI-ADC for response assessment and survival prediction
por: Lombardi, Giuseppe, et al.
Publicado: (2022)

Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview
por: Lombardi, Giuseppe, et al.
Publicado: (2022)

Serum Exosomal microRNA-21, 222 and 124-3p as Noninvasive Predictive Biomarkers in Newly Diagnosed High-Grade Gliomas: A Prospective Study
por: Olioso, Debora, et al.
Publicado: (2021)

The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Advanced Adrenocortical Carcinoma: From Symptoms Control to Palliative Care
por: Ruggiero, Elena, et al.
Publicado: (2022)

Sustained Accumulation of Blood-Derived Macrophages in the Immune Microenvironment of Patients with Recurrent Glioblastoma after Therapy
por: Magri, Sara, et al.
Publicado: (2021)

SYST-20 TARGETED THERAPY MATCHED TO GENOMIC ALTERATIONS (BRAFV600E, NTRK, FGFR, ROS1, PIK3CA, PTEN) IN PATIENTS WITH RECURRENT IDH WILDTYPE GLIOBLASTOMA: A REAL-LIFE COHORT ANALYSIS FROM VENETO INSTITUTE OF ONCOLOGY, PADUA (ITALY)
por: Padovan, Marta, et al.
Publicado: (2023)

Urine 2-Hydroxyglutarate in Glioma
por: Lombardi, Giuseppe, et al.
Publicado: (2016)

Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients
por: Giunco, S., et al.
Publicado: (2023)

The Overall Survival and Progression-Free Survival in Patients with Advanced Adrenocortical Cancer Is Increased after the Multidisciplinary Team Evaluation
por: Tizianel, Irene, et al.
Publicado: (2022)

Mismatch-Repair Protein Expression in High-Grade Gliomas: A Large Retrospective Multicenter Study
por: Caccese, Mario, et al.
Publicado: (2020)

Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study
por: Caccese, Mario, et al.
Publicado: (2023)

Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study
por: Brandes, Alba A., et al.
Publicado: (2017)

Treatment of Malignant Gliomas in Elderly Patients: A Concise Overview of the Literature
por: Farina, Patrizia, et al.
Publicado: (2014)

Magnetic Resonance Imaging Correlates of Immune Microenvironment in Glioblastoma
por: Salvalaggio, Alessandro, et al.
Publicado: (2022)

Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study
por: Caccese, Mario, et al.
Publicado: (2022)

Newly Diagnosed Multifocal GBM: A Monocentric Experience and Literature Review
por: Baro, Valentina, et al.
Publicado: (2022)

An Overview of Intracranial Ependymomas in Adults
por: Lombardi, Giuseppe, et al.
Publicado: (2021)

Recurrent Glioblastoma: What Is the Route?
por: Bosio, Alberto, et al.
Publicado: (2023)

Seizures, Edema, Thrombosis, and Hemorrhages: An Update Review on the Medical Management of Gliomas
por: Zoccarato, Marco, et al.
Publicado: (2021)

Innovating Strategies and Tailored Approaches in Neuro-Oncology
por: Picca, Alberto, et al.
Publicado: (2022)

Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study
por: Lombardi, Giuseppe, et al.
Publicado: (2020)

An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Caring for Patients with Advanced Stage Cancer at the Time of COVID‐19
por: Brunello, Antonella, et al.
Publicado: (2020)

Cancer Patient-Reported Experience Measures (PREMs) Regarding the Policies Implemented to Contain the Spread of Sars-CoV-2 and Vaccination Campaign at Veneto Institute of Oncology
por: Caccese, Mario, et al.
Publicado: (2022)

Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives
por: Weenink, Bas, et al.
Publicado: (2020)

Patterns of gray and white matter functional networks involvement in glioblastoma patients: indirect mapping from clinical MRI scans
por: Sansone, Giulio, et al.
Publicado: (2023)

Antigen rapid diagnostic test monitoring for SARS‐CoV‐2 in asymptomatic and fully vaccinated cancer patients: Is it cost‐effective?
por: Caccese, Mario, et al.
Publicado: (2022)

Case report: The lesson from opioid withdrawal symptoms mimicking paraganglioma recurrence during opioid deprescribing in cancer pain
por: Ruggiero, Elena, et al.
Publicado: (2023)

Glioblastoma in Elderly Patients: Current Management and Future Perspectives
por: Minniti, Giuseppe, et al.
Publicado: (2019)

Gliomas
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices
por: Di Cintio, Federica, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_diott9743s55b2jefhsek5kmp8